Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123

• Published in: Nature biotechnology Vol. 41; no. 9; pp. 1296 - 1306
• Main Authors: Gauthier, Laurent, Virone-Oddos, Angela, Beninga, Jochen, Rossi, Benjamin, Nicolazzi, Céline, Amara, Céline, Blanchard-Alvarez, Audrey, Gourdin, Nicolas, Courta, Jacqueline, Basset, Alexandra, Agnel, Magali, Guillot, Franceline, Grondin, Gwendoline, Bonnevaux, Hélène, Bauchet, Anne-Laure, Morel, Ariane, Morel, Yannis, Chiron, Marielle, Vivier, Eric
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.09.2023; Nature Publishing Group
• Subjects: 631/154/51/1568; 631/250/251; 631/61/24; 631/67/1059/2325; Acute myeloid leukemia; Agriculture; Animals; Antibodies; Antibody-Dependent Cell Cytotoxicity; Anticancer properties; Antitumor activity; Bioinformatics; Biomedical and Life Sciences; Biomedical Engineering/Biotechnology; Biomedicine; Biotechnology; Cancer; CD123 antigen; Cell activation; Clinical trials; Cytokines; Cytokines - metabolism; Cytotoxicity; Hematology; Human health and pathology; Humans; Immunoglobulin G; Immunology; Immunotherapy; Inflammation; Interleukin-3 Receptor alpha Subunit; Killer Cells, Natural; Leukemia; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - metabolism; Life Sciences; Lymphocytes; Lymphocytes T; Mice; Natural killer cells; Pharmacodynamics; Receptors; T-Lymphocytes; Toxicity

CD123, the alpha chain of the IL-3 receptor, is an attractive target for acute myeloid leukemia (AML) treatment. However, cytotoxic antibodies or T cell engagers targeting CD123 had insufficient efficacy or safety in clinical trials. We show that expression of CD64, the high-affinity receptor for hu...